The role of drug-metabolising enzymes in clinical responses to chemotherapy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 1, 2006, Pages 17-25

  Scripture, Charity D ^a   Figg, William D ^a   Sparreboom, Alex ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer chemotherapy; Cytochrome P450; Genotype; Interindividual variability; Pharmacogenomics

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 3A4; DEXAMETHASONE; DOCETAXEL; DRUG METABOLIZING ENZYME; NAVELBINE;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER THERAPY; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; GENE STRUCTURE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PHENOTYPE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; NEOPLASMS; PHENOTYPE; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 33846261196     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.1.17     Document Type: Review

References (76)

1. SCRIPTURE CD, SPARREBOOM A, FIGG WD: Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. (2005) 6(10):780-789.
2. EVANS WE, MCLEOD HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. (2003) 348(6):538-549.
3. EVANS WE, RELLING MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 286(5439):487-491.
4. MCLEOD HL, EVANS WE: Pharmacogenomics: unlocking the human genome for better drug therapy. Ann. Rev. Pharmacol. Toxicol. (2001) 41:101-121.
5. ANDO Y: Cytochrome P450 and Anticancer Drugs. In: Handbook of AntiCancer Pharmacokinetics and Pharmacodynamics. WD Figg, HL McLeod (Eds), Humana Press, Totowa, NJ, USA (2004).
6. COULTHARD SA, BODDY AV: Metabolism (Non-CYP Enzymes). In: Handbook of Anti-Cancer Pharmacokinetics and Pharmacodynamics. WD Figg, HL McLeod (Eds), Humana Press, Totowa, NJ, USA (2004).
7. MEYER UA: Overview of enzymes of drug metabolism. J. Pharmacokinet. Biopharm. (1996) 24(5):449-459.
8. WRIGHTON SA, STEVENS JC: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. (1992) 22(1):1-21.
9. CHANG TK, WEBER GF, CRESPI CL, WAXMAN DJ: Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res. (1993) 53(23):5629-5637.
10. BODDY AV, YULE SM: Metabolism and pharmacokinetics of oxazaphosphorines. Clin. Pharmacokinet. (2000) 38(4):291-304.
11. ROY P, YU LJ, CRESPI CL, WAXMAN DJ: Development of a substrate-activity based approach to identity the major human liver P450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P450 profiles. Drug Metab. Dispos. (1999) 27(6):655-666.
12. HUANG Z, ROY P, WAXMAN DJ: Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol. (2000) 59(8):961-972.
13. RAHMAN A, KORZEKWA KR, GROGAN J, GONZALEZ FJ, HARRIS JW: Selective biotransformation of taxol to 6-α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. (1994) 54(21):5543-5546.
14. HICHIYA H, TANAKA-KAGAWA T, SOYAMA A a al.: Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R and K383N, found in a Japanese population. Drug Metab. Dispos. (2005) 33(5):630-636.
15. BAHADUR N, LEATHART JB, MUTCH E et al.: CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6-α-hydroxylase activity in human liver microsomes. Biochem. Pharmacol. (2002) 64(11):1579-1589.
16. SOYAMA A, SAITO Y, HANIOKA N et al.: Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol. Pharm. Bull. (2001) 24(12):30.
17. SOYAMA A, SAITO Y, KOMAMURA K et al.: Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab. Pharmacokinet. (2002) 17(4):374-377.
18. DAI D, ZELDIN DC, BLAISDELL JA et al.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics (2001) 11(7):597-607.
19. NAKAJIMA M, FUJIKI Y, KYO S et al.: Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J. Clin. Pharmacol. (2005) 45(6):674-682.
20. HENNINGSSON A, MARSH S, LOOS WJ, SPARREBOOM A: Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin. Cancer Res. (2005) 11(22):8097-8104.
21. MA JD, NAFZIGER AN, BERTINO JS Jr: Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers. J. Clin. Pharmacol. (2004) 44(5):447-456.
22. HIGASHI MK, VEENSTRA DL, KONDO LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 287(13):1690-1698.
23. VAN DER WEIDE J, STEIJNS LS, VAN WEELDEN MJ, DE HAAN K: The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics (2001) 11(4):287-291.
24. ANDO Y, PRICE DK, DAHUT WL et al.: Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol. Ther. (2002) 1(6):669-673.
25. PRICE DK, ANDO Y, KRUGER EA, WEISS M, FIGG WD: 5′-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis. Ther. Drug Monit. (2002) 24(1):104-110.
26. DEHAL SS, KUPFER D: CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. (1997) 57(16):3402-3406.
27. MANI C, GELBOIN HV, PARK SS et al.: Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. (1993) 21(4):645-656.
28. SRIDAR C, KENT UM, NOTLEY LM, GILLAM EM, HOLLENBERG PF: Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J. Pharmacol. Exp. Ther. (2002) 301(3):945-952.
29. DESTA Z, WARD BA, SOUKHOVA NV, FLOCKHART DA: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. (2004) 310(3):1062-1075.
30. CREWE HK, ELLIS SW, LENNARD MS, TUCKER GT: Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. (1997) 53(2):171-178.
31. DESTA Z, WARD BA, SOUKHOVA NV, FLOCKHART DA: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. (2004) 310(3):75.
32. STEARNS V, JOHNSON MD, RAE JM et al.: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. (2003) 95(23):64.
33. SHIMADA T, YAMAZAKI H, MIMURA M, INUI Y, GUENGERICH FP: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. (1994) 270(1):414-423.
34. OZDEMIR V, KALOWA W, TANG BK et al.: Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics (2000) 10(5):373-388.
35. SCRIPTURE CD, SPARREBOOM A, FIGG WD: Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. (2005) 6(10):780-789.
36. MARRE F, SANDERINK GJ, DE SOUSA G et al.: Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res. (1996) 56(6):1296-1302.
37. SHOU M, MARTINET M, KORZEKWA KR et al.: Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics (1998) 8(5):391-401.
38. CLARKE SJ, RIVORY LP: Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet. (1999) 36(2):99-114.
39. HIRTH J, WATKINS PB, STRAWDERMAN M et al.: The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin. Cancer Res. (2000) 6(4):1255-1258.
40. YAMAMOTO N, TAMURA T, KAMIYA Y et al: Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J. Clin. Oncol. (2000) 18(11):2301-2308.
41. ENGELS FK, TEN TIJE AJ, BAKER SD et al.: Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin. Pharmacol. Ther. (2004) 75(5):448-454.
42. GOH BC, LEE SC, WANG LZ et al.: Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. (2002) 20(17):3683-3690.
43. HEGGIE GD, SOMMADOSSI JP, CROSS DS, HUSTER WJ, DIASIO RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. (1987) 47(8):2203-2206.
44. LU Z, ZHANG R, DIASIO RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. (1993) 53(22):5433-5438.
45. ETIENNE MC, LAGRANGE JL, DASSONVILLE O et al.: Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. (1994) 12(11):2248-2253.
46. RIDGE SA, SLUDDEN J, BROWN O et al.: Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br. J. Clin. Pharmacol. (1998) 46(2):151-156.
47. RIDGE SA, SLUDDEN J, WEI X et al.: Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br. J. Cancer (1998) 77(3):497-500.
48. RELLING MV, DERVIEUX T: Pharmacogenetics and cancer therapy. Nat. Rev. Cancer (2001) 1(2):99-108.
49. JOHNSON MR, HAGEBOUTROS A, WANG K et al.: Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin. Cancer Res. (1999) 5(8):2006-2011.
50. VAN KUILENBURG AB, MULLER EW, HAASJES J et al.: Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G > A mutation causing DPD deficiency. Clin. Cancer Res. (2001) 7(5):1149-1153.
51. MAGNE N, RENEE N, FORMENTO J et al.: Prospective study of dihydropyrimidine dehydrogenase (DPD) activity and DPYD IVS14+1G > A mutation in patients developing FU-related toxicities: an updated analysis based on a ten-year recruitment across multiple French institutions. Proc. Am. Soc. Clin. Oncol. (2005) 23(16S):2003.
52. JIN Y, DESTA Z, STEARNS V et al.: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. (2005) 97(1):30-39.
53. SWEENEY C, MCCLURE GY, FARES MY et al.: Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res. (2000) 60(20):5621-5624.
54. MARSH S, MCLEOD HL: Cancer pharmacogenetics. Br. J. Cancer (2004) 90(1):8-11.
55. HEIN DW, DOLL MA, FRETLAND AJ et al.: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. (2000) 9(1):29-42.
56. RATAIN MJ, MICK R, BEREZIN F et al.: Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin. Pharmacol. Ther. (1991) 50(5 Pt 1):573-579.
57. RATAIN MJ, MICK R, BEREZIN F et al.: Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. (1993) 53(10 Suppl.):2304-2308.
58. RATAIN MJ, MICK R, JANISCH L et al.: Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics (1996) 6(1):93-101.
59. EVANS WE: Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther. Drug Monit. (2004) 26(2):186-191.
60. EVANS WE, HORNER M, CHU YQ, KALWINSKY D, ROBERTS WM: Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr. (1991) 119(6):985-989.
61. LENNARD L, LILLEYMAN JS: Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J. Clin. Oncol. (1989) 7(12):1816-1823.
62. LENNARD L, LILLEYMAN JS, VAN LOON J, WEINSHILBOUM RM: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet (1990) 336(8709):225-229.
63. RELLING MV, HANCOCK ML, RIVERA GK et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer Inst. (1999) 91(23):2001-2008.
64. PULLARKAT ST, STOEHLMACHER J, GHADERI V et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. (2001) 1(1):65-70.
65. ANDO Y, SAKA H, ASAI G et al.: UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann. Oncol. (1998) 9(8):845-847.
66. ANDO Y, SAKA H, ANDO M et al.: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. (2000) 60(24):6921-6926.
67. IYER L, DAS S, JANISCH L et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. (2002) 2(1):43-47.
68. INNOCENTI F, UNDEVIA SD, IYER L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. (2004) 22(8):1382-1388.
69. ULRICH CM, ROBIEN K, MCLEOD HL: Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat. Rev. Cancer (2003) 3(12):912-920.
70. BACHMANN KA: Genotyping and phenotyping the cytochrome P450 enzymes. Am. J. Ther. (2002) 9(4):309-316.
71. SLAVIERO KA, CLARKE SJ, MCLACHLAN AJ, BLAIR EY, RIVORY LP: Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br. J. Clin. Pharmacol. (2004) 57(1):44-53.
72. BAKER SD, TEN TIJE AJ, CARDUCCI MA et al.: Evaluation of CYP3A activity as a predictive covariate for docetaxel clearance. Proc. Am. Soc. Clin. Oncol. (2004) 23(128s):2006.
73. PUISSET F, CHATELUT E, DALENC F et al.: Dexamethasone as a probe for docetaxel clearance. Cancer Chemother. Pharmacol. (2004) 54(3):72.
74. YAMAMOTO N, TAMURA T, MURAKAMI H et al.: Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous Cortisol. J. Clin. Oncol. (2005) 23(6):1061-1069.
75. http://www.imm.ki.se/cypalleles/
76. http://www.fda.gov/cder/foi/label/2005/020571s024,028lbl.pdf.